CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $8
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
H.C. Wainwright Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $9
Cardiol Therapeutics' CardiolRx Gains Buy Rating on Positive Phase 2 Results and Strong Financial Position
Cardiol Therapeutics Analyst Ratings
H.C. Wainwright Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $9
Roth MKM Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $10
Cardiol Therapeutics (CRDL) Gets a Buy From Roth MKM
CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $8
Roth MKM Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $10
Cardiol Therapeutics Analyst Ratings
ROTH MKM Initiates Coverage on Cardiol Therapeutics With Buy Rating, $10 Price Target
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
Cardiol Therapeutics Analyst Ratings
Cardiol Therapeutics Analyst Ratings
Cardiol Therapeutics Analyst Ratings
Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $8
Cardiol Therapeutics Inc: Canaccord Genuity raises price target from $6 to $8
HC Wainwright & Co. : The Cardiol Therapeutics (CRDL.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $9.00.
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target